New generation of
smarter medicines
Developing differentiated
cancer therapeutics
Senti Bio is a clinical-stage company founded to create a new generation of smarter medicines for patients living with incurable diseases. To achieve this, we use synthetic biology to design and optimize proprietary Gene Circuits. Senti Bio’s Gene Circuits are created from novel combinations of DNA sequences to reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments. Using Gene Circuits, our therapeutics are designed to precisely kill cancer cells, spare healthy cells, increase specificity to target cells and control the expression of drugs even after administration.
We are applying our Gene Circuit technologies to develop a pipeline of product candidates that use off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells with the goal of addressing major challenges and providing potentially lifesaving treatments for people living with cancer.
Engineering smarter
medicines by programming
cells with Gene Circuits
Senti Bio is primarily focused on advancing off-the-shelf CAR-NK cell therapy programs for oncology indications. Our lead product candidate SENTI-202 is in the clinic in the U.S. for the treatment of acute myeloid leukemia (AML). We also have three partnered programs: SENTI-301A for the treatment of hepatocellular carcinoma (HCC) being evaluated in a clinical trial in China in partnership with Celest Therapeutics, our partnership program related to gene therapies for tissue-directed targets with Spark Therapeutics, and our partnership program related to cell therapies for regenerative medicines with BlueRock Therapeutics.
“The field of synthetic biology has evolved rapidly over the past few decades. We believe that we are uniquely positioned to harness its potential to drive significant advances in medicine.”
Tim Lu, MD, PhD
Co-Founder and CEO, Senti Bio
